Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medicure Inc V.MPH

Alternate Symbol(s):  MCUJF

Medicure Inc. is a Canada-based pharmaceutical company. The Company is focused on the development and commercialization of therapies for the United States cardiovascular market. The focus of the Company is the marketing and distribution of AGGRASTAT (tirofiban hydrochloride) injection and ZYPITAMAG (pitavastatin) tablets in the United States, where they are sold through the Company’s United States subsidiary, Medicure Pharma Inc. The Company also operates Marley Drug, Inc. (Marley Drug), a pharmacy located in North Carolina that offers an Extended Supply drug program serving all 50 states, Washington D.C. and Puerto Rico. Marley Drug is committed to improving the health status of its patients and the communities they serve while reducing overall health care costs for employers and other health care consumers. AGGRASTAT is indicated to reduce the rate of thrombotic cardiovascular events in patients with non-ST elevation acute coronary syndrome (NSTE-ACS).


TSXV:MPH - Post by User

Bullboard Posts
Comment by newcomer21on Aug 18, 2003 5:02pm
187 Views
Post# 6332469

Bert Friesen

Bert FriesenOne of the main reasons that I bought MPH was because of my knowledge of the CEO. I have known Bert Friesen for 28 years. After completing his Ph. D. he began to develop patents and enterprises that utilized some of the drug discoveries that were being made at the University of Manitoba. For a time he was employed by the University of Manitoba and then he launched his career as an entrepreneur. During an interview on ROB t.v. one year ago, Bert Friesen displayed his typical candor. He said that Biotech depends on luck. Plain and simple. If you have a substance that can withstand the rigors of scientific evaluation you can do very well. But, if the results aren't there you can do poorly too and it is difficult to know how things will turn out until the science is done. That is what I expect in a CEO. Candor and honesty. Bert has that and I invested in the company soon after that interview after watching MPH for two full years. It was down to .50 cents and it looked like a good time to get in. I have since halved my holdings. Anyone who risks everything in a biotech is not an experienced investor.
Bullboard Posts